Athenex's KX2-391 completes patient enrollment for both Phase III clinical studies months ahead of schedule [Seeking Alpha]
Athenex, Inc. (ATNX)
Last athenex, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.athenex.com
Company Research
Source: Seeking Alpha
Athenex's KX2-391 completes patient enrollment for both Phase III clinical studies months ahead of scheduleAthenex (ATNX-0.5%)reports Q1 revenue growth of 726% Y/Y to $37.8M; the increase was due to $25M in upfront license fees related to the collaboration agreement with Almirall, S.A; $8.6M specialty products sold through commercial platform & $0.4M sales of 503B products.R&D expense reduced by 19% Y/Y to -$21.3M majorly due to $14.4M decreased of drug licensing fees to Hanmi & Gland; and offset by $6.9M increase of clinical study costs for Phase III trials of Oraxol and KX-01 Ointment.Clinical Platforms: Received Orphan Drug Designation from the US FDA for Oraxol in angiosarcoma; met & exceeded enrollment target for Oraxol Phase III Clinical Trial in metastatic breast cancer & announced positive feedback from the FDA; KX2-391 Ointment completes patient enrollment for both Phase III clinical studies months ahead of schedule.Commercial Business: Launched 8 new products; Athenex Pharma
Show less
Read more
Impact Snapshot
Event Time:
ATNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATNX alerts
High impacting Athenex, Inc. news events
Weekly update
A roundup of the hottest topics